Category Archives: Stem Cell Research

Big News! I Got a Job Follow Me - https://twitter.com/BrainstormSci Some Articles ... By: qdragon1337 … Continue reading →

PBR Staff Writer Published 26 March 2015 AstraZeneca has signed a five-year collaboration deal with the Harvard Stem Cell Institute (HSCI), under which the parties will investigate adapting a technique to create human beta cells from stem cells for use in finding new treatments for diabetes. As part of the deal, AstraZeneca will provide funding for a team of investigators at Harvard and will establish an in-house team in Sweden which will work on the collaboration. The team at Sweden is led by HSCI co-chairman and Howard Hughes Medical Institute Investigator, Dr Doug Melton. The deal aims to better understand how the function of beta cells reduces in diabetes and provide research findings to the broader scientific community through peer-reviewed publications. Under the deal, scientists from both the parties will jointly work to understand the biology behind the loss of human beta cell function and mass in diabetes. They will also be responsible for screening compounds against the cells produced to search for potential new medicines that could restore beta cell activity in diabetic patients. AstraZeneca Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development head Marcus Schindler said: "We are excited about the potential of this latest collaboration with … Continue reading →

A Kantian Response to the Human Embryonic Stem Cell Research Debate Assemblies of God (2014) - From the 2014 Faith Science Conference, Paige Erickson and Russell Fail engage in a philosophical discussion that argues the logical superiority of a Kantian approach... By: Theology, Philosophy and Science … Continue reading →

L: The Asahi Shimbun via Getty/R: Kyodo via Newscom RIKEN president Ryoji Noyori (left) at his resignation press conference. He will be replaced by Hiroshi Matsumoto (right, pictured at a Kyoto University press conference in 2011). Ryoji Noyori, long-time president of Japan's RIKEN network of basic-research laboratories, has resigned after a year in which the organization was embroiled in controversy over fraudulent stem-cell papers. The 76-year-old Nobel-prizewinning chemist had headed RIKEN since October 2003, and was in the middle of his third five-year term. At a press conference on 24 March, RIKEN revealed Noyoris successor as of 1 April: Hiroshi Matsumoto, a former president of Kyoto University and an expert in space plasma physics. RIKEN, which will celebrate its centenary in 2017, employs more than 2,800 scientists on campuses across Japan, and commanded a 2012 budget of some 90 billion (at the time, around US$1.1 billion). In a statement posted on RIKEN's website, Noyori congratulated the institute on several achievements during his presidency, including the discovery of element 113, the establishment of the SACLA X-ray Free Electron Laser and the K supercomputer, and the worlds first clinical trial using induced pluripotent stem cells. RIKEN has attracted numerous outstanding scientists from … Continue reading →

5th World Congress on Cell Stem Cell Research 5th World Congress on Cell Science Stem Cell Research, March 23-25, Chicago, USA has the goal to fill the prevailing gaps in the transformation of this science of hope to serve all in needs.... By: OMICS International … Continue reading →

Cell Stem Cell Research relevant conference 2015 5th World Congress on Cell Science Stem Cell Research, March 23-25, Chicago, USA has the goal to fill the prevailing gaps in the transformation of this science of hope to serve all in needs.... By: OMICS International … Continue reading →

IMAGE:Karsten Sauer, Ph.D., is an associate professor at The Scripps Research Institute. view more Credit: Photo courtesy of The Scripps Research Institute. LA JOLLA, CA - March 23, 2015 - Stem cells can generate any type of cell in the body, but they are inactive most of the time--and for good reason. When stem cells become too active and divide too often, they risk acquiring cell damage and mutations. In the case of blood stem cells (also called hematopoietic stem cells or HSCs), this can lead to blood cancers, a loss of blood cells and an impaired ability to fight disease. Now scientists at The Scripps Research Institute (TSRI) have found that a particular enzyme in HSCs is key to maintaining healthy periods of inactivity. Their findings, published recently in the journal Blood, show that animal models without this enzyme experience dangerous HSC activation and ultimately succumb to lethal anemia. "These HSCs remain active too long and then disappear," said TSRI Associate Professor Karsten Sauer, senior author of the new study. "As a consequence, the mice lose their red blood cells and die." With this new understanding of the enzyme, called Inositol trisphosphate 3-kinase B (ItpkB), scientists are closer to … Continue reading →

WSCS 2014: HUMAN EGGS IN STEM CELL RESEARCH AND REPRODUCTION Presenter - Dieter Egli, New York Stem Cell Foundation. By: worldstemcell … Continue reading →

Investigational Therapies and Stem Cell Research in PAH From PHA's 2014 International PH Conference and Scientific Sessions. Panelists: Raymond Benza, MD* (Allegheny General Hospital, Pittsburgh, Pa.) Vallerie McLaughlin, MD (University of Michigan... By: PHAssociation … Continue reading →

The International Society for Stem Cell Research has released a statement calling for a moratorium on attempts to apply nuclear genome editing of the human germ line in clinical practice In a statement released yesterday, the International Society for Stem Cell Research called for a moratorium on attempts at clinical application of nuclear genome editing of the human germ line to enable more extensive scientific analysis of the potential risks of genome editing and broader public discussion of the societal and ethical implications. Technologies used to introduce changes into the DNA sequence of cells have advanced rapidly, making genome editing increasingly simple. Genome editing is feasible, not just in the somatic cells of an adult organism, but also in early embryos, as well as the gametes (sperm and egg) that carry the inheritable, germline DNA. Research involving germline nuclear genome editing has been performed to date in many organisms, including mice and monkeys, and applications to human embryos are possible. The ISSCR statement raises significant ethical, societal and safety considerations related to the application of nuclear genome editing to the human germ line in clinical practice. Current genome editing technologies carry risks of unintended genome damage, in addition to unknown … Continue reading →